Harfst & Associates’s Pfizer PFE Stock Holding History

Harfst & Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-362	Closed	-$11K	–	283
2017 Q1	$11K	Buy	+362	New	+$11.4K	﹤0.01%	229

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harfst & Associates's PFE Position: Q2 2017 in Review

Harfst & Associates sold out of Pfizer (PFE) in Q2 2017, closing a stake of 362 shares — an estimated $11K sold.

Harfst & Associates first reported a position in PFE in Q1 2017 and held it in 1 quarter. The position peaked at $11K in Q1 2017. 2,050 funds tracked by Wall St. Rank hold PFE as of Q2 2017.

Harfst & Associates reported no remaining Pfizer position as of Q2 2017 after selling out during the quarter.
Harfst & Associates sold 362 Pfizer shares in Q2 2017, an estimated $11K.
Harfst & Associates first reported a position in Pfizer in Q1 2017 and held it in 1 quarter.
Harfst & Associates's Pfizer position peaked at $11K in Q1 2017.
2,050 funds tracked by Wall St. Rank held Pfizer as of Q2 2017.

Based on Harfst & Associates's 13F filing for Q2 2017, filed 11 Aug 2017.